ZVRA - Zevra Therapeutics, Inc.
NEXT EARNINGS:
Mar 10, 2026
(in 13 days)
EPS Est: $0.05
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$24.67
DETAILS
HIGH:
$26.00
LOW:
$24.00
MEDIAN:
$24.00
CONSENSUS:
$24.67
UPSIDE:
175.03%
Market Cap:
504.99M
Volume:
381,915
Avg Volume:
955,900
52 Week Range:
6.19-13.16
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.92
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
59
IPO Date:
2015-04-16
EPS (TTM):
-2.28
P/E Ratio:
-3.66
Revenue (TTM):
23.61M
Total Assets:
178.13M
Total Debt:
60.30M
Cash & Equiv:
33.78M
Rev Growth (5Y):
13.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-57.5%
Debt/Equity:
1.52
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-0.01 | $-0.02 | +50.0% | $26.1M | $26.6M | -2.2% |
| 2025-08-12 | $1.21 | $2.19 | -44.7% | $25.9M | $24.5M | +5.6% |
| 2025-05-13 | $-0.06 | $-0.21 | +71.4% | $20.4M | $21.1M | -3.2% |
| 2025-03-11 | $-0.67 | $-0.39 | -71.8% | $12.0M | $16.7M | -27.7% |
| 2024-11-12 | $-0.69 | $-0.44 | -56.8% | $3.7M | $8.8M | -57.9% |
| 2024-08-13 | $-0.48 | $-0.47 | -2.1% | $4.4M | $4.4M | +2.0% |
| 2024-05-08 | $-0.40 | $-0.49 | +18.4% | $3.4M | $4.7M | -26.3% |
| 2024-03-28 | $-0.40 | $-0.20 | -100.0% | $13.2M | $11.7M | +12.6% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.61M | 27.46M | 10.16M | 28.65M | 13.29M | 12.84M | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (105.51M) | (46.05M) | (26.77M) | (8.55M) | (12.76M) | (24.52M) | (56.47M) | (43.39M) | (16.52M) | (54.66M) | (24.45M) | (5.23M) |
| EPS | -2.28 | -1.30 | -0.78 | -2.11 | -3.21 | -13.23 | -50.39 | -47.37 | -18.10 | -118.69 | -31.79 | -10.69 |
| Total Assets | 178.13M | 172.33M | 115.34M | 132.94M | 11.21M | 10.51M | 26.75M | 52.46M | 84.89M | 55.72M | 13.71M | 2.43M |
| Total Debt | 60.30M | 43.77M | 18.78M | 1.61M | 70.55M | 79.53M | 82.05M | 93.48M | 91.98M | 23.10M | 18.95M | 3.97M |
| Cash & Equivalents | 33.78M | 43.05M | 65.47M | 112.35M | 4.21M | 3.22M | 18.41M | 10.87M | 16.76M | 32.32M | 10.26M | 1.97M |
| Operating Cash Flow | (69.67M) | (33.53M) | (18.72M) | 10.44M | (1.94M) | (23.74M) | (54.20M) | (33.10M) | (29.77M) | (20.27M) | (14.67M) | (4.33M) |
| Free Cash Flow | (69.67M) | (33.83M) | (18.81M) | 10.34M | (1.97M) | (23.76M) | (54.22M) | (33.28M) | (30.41M) | (20.40M) | (14.72M) | (4.38M) |
| FCF per Share | -1.51 | -0.95 | -0.55 | 0.35 | -0.50 | -12.82 | -48.39 | -36.34 | -33.34 | -44.30 | -19.14 | -8.95 |
| Book Value | 39.67M | 61.86M | 75.12M | 127.12M | (66.41M) | (74.46M) | (66.57M) | (57.52M) | (18.70M) | (10.12M) | (24.30M) | (24.27M) |
| Cash & ST Investments | 69.50M | 67.74M | 82.85M | 112.35M | 4.21M | 3.22M | 21.67M | 42.23M | 67.77M | 51.32M | 10.26M | 1.97M |
| ROC Equity | -2.66 | -0.74 | -0.36 | -0.07 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |